前苏联专利SU1468419A3 Method of producing derivatives of 1,2-benzisoxazolyl-3, or 1,2-benzisothiazolyl-3 or stereosiomers

专利PDF首页>>前苏联专利

专利附录

专利说明

权利要求

类似技术

同族专利

引用文献

法律状态

优先权

专利摘要:
Novel 3-piperidinyl-1,2-benzisothiazoles and 3-piperidinyl-1,2-benzisoxazoles having the formula wherein X is O or S and Q is a radical of formula or a radical of formula the pharmaceutically acceptable acid addition salts and possible stereochemically isomeric forms thereof, which compounds have antipsychotic properties; pharmaceutical compositions containing such compounds as an active ingredient and methods of preparing said compounds and pharmaceutical compositions.
公开号:SU1468419A3
申请号:SU864027047
申请日:1986-03-05
公开日:1989-03-23
发明作者:Эдмон Жозефин Кеннис Людо；Ванденберк Ян
申请人:Жансен Фармасетика Н.В. (Фирма)；
IPC主号:

专利说明:

1468419
The invention relates to the field of obtaining new heterocyclic compounds, in particular, derivatives of 15.2-benzisooxazoln-3 or 1,2-j benzisothiaoolyl-3 of the general formula
(I)
Q
-AlK-NO-C
e R R "XAlkQ hydrogen, halogen, hydroxyl
or methoxy;
vy ;; city or halogen;
O or S;
Sz-C-alkylene;
group of general formula
AND
N L (a);
R. 1
gbt
about
Y - O or S ;.
RJ is hydrogen, OH, C, -C4-alkoxy 25
or C, -C4-alkyl; R is hydrogen or halogen, or Q is a group of the general formula
N
ABOUT
de RS is hydrogen or C, -C4 alkyl;
Z is S, CH.2 or -CRj, CRf-, where 35 is 6, and RT is independently hydrogen or ap kil; And - With - With - a capkilen or, -,
where Rg and R, - independently40
from each other With :, -C4-alkyl or halogen,
whether their stereoisomers, or their acid addition salts, possessing psychotic and antiserotonin activity 45.
The purpose of the invention is to create, on the basis of known methods, a method of obtaining new compounds with high psychotic and anti-serotinin activity.
Example 1. A mixture of 5.3 g of 3- (2-chloro-ethylate 1) -6,7,8,9-tetrahydro-2-methyl-4H-pyrido 1,2-a pyrimidin-4-on-hydrochloride, 4, 4 g of 6-fluoro-3- (4-piperidinyl) -1,2-benzisoxazole, 8 parts of sodium carbonate, 0.1 parts of potassium iodide and 90 hours, H, K-dimethylformamide is stirred overnight at 85-90 С,
j
o
five
0
five
thirty
35
40
45
50
55
After cooling, the reaction mixture is poured into water. The product is filtered and crystallized from a mixture of N, N-dimethylformamide and 2-propanol. The product is filtered and dried, yielding 3.8 g (46%) (6-fluoro-1,2-benzisoxazol-3-yl) -1-piperidyl, 7,7,9-tetr-agidro-2-metip-4H- Ttirido 1,2-a pyrimidin-4-one, so pl. 170.0 ° C (compound 1).
Following the same method and using equivalent amounts of corresponding CTBympijix starting materials, also receive :,
(6-fluoro-1,2-benzisoxazole-3-yl) -1-piperidinylZ ethyl 3-7-methyl-5H-thiazoloGs, 2-a pyrimidine-5-one,
m.p. 65, ° C (compound 2);
(1,2-benzisoxazol-3-yl) -1-piperidinyl ethyl -2-methyl-4H-pyrido 1,2-a pyrimid {-4-one, m.p. 177.9 ° C (compound 3);
(6-fluoro-1,2-benzisoxazole-3-yl) -1-piperidinyl 3, 7-dimethyl-4H-pyrrido 1,2-a pyrimidine-4-one, mp. 186.9 ° C (compound 4);
3- 2-t4- (l, 2-benzisoxazol-3-yl) -1-piperidinylZethyl-6,7,8,9-tetrahydro-2-methyl-4H-pyrido l, 2-a | pyrimidine -4-OH, m.p. 183.1 ° C (compound 5);
3- (1,2-benzisothiazol-3-yl) - 1-piperidinylZetil -2,4- (1H, 3N) - quinazoline hydrochloride, t.gsh. 300 C (compound 6);
(1,2-benzisothiazol-3-yl) - 1-piperidinyl ethyl-6,7,7,8-tetrahydro-2-methyl-4H-pyrido D, 2-aZpyrimidin-4-OH, t. gsh 145.7 ° C (compound 7);
(6-hydroxy-1,2-benzisoxazol-3-yl) -1-piperidinyl 6,7,8,9-tetrahydro-2-methyl-4H-pyrido (1,2-a pyrimidine-4- he, mp 213, (compound 8).
Similarly, receive
3- (5-methoxy-1,2-benzisoxazole-3-sh1) -1-piperidinyl ethyl -2-methyl-4H-pyrido 1, 2-a pyrimidin-4-one (compound 9);
(6-fluoro-1,2-benzisoxazol-3-ip) -1-piperidinyl etypZ-2-methyl-4H-pyrido l, 2-aZpyrimidine-4-0n (compound 10).
PRI mme R 2. A mixture of 3.3 g 3- (1-chloroethig1) -2-methyl-4H-pyrido l, 2-a pyrimidin-4-one, 3.3 g 6-fluoro-3- (4-piperidinyl) -1,2-benzyl oxazole, 8 g of sodium carbonate, 1 g of potassium iodide, and 20 g of 4-methyl-2-pentano- n are stirred and refluxed for 3 hours. The reaction mixture is cooled, water is added and the layers are separated. The organic phase is purified by capillary chromatography I on silica gel using a mixture of trichloromethane and methanol (95: 5 by volume) as elkzent. The pure fractions are collected and the eluent is evaporated. The residue is crystallized in 4-metsh-1-2-pentanone, which gives 1.2 g (19%) (6-fluoro-1,2-benzisoxol-3-yl) -1-piperidium or methyl 2-metep-4H- pyrido l, 2-a pyrimidin-4-she, t, pl. 170.4 ° C (same as 1).
Example 3. A mixture of 6.75 g of 3- (2-chloroethyl) -2,4- (1H, 3N) -quinazol-idion, 6.6 g of 6-fluoro-3- (4-piperidinyl) -1 , 2-benzisoxazole, 10 g of sodium bicarbonate, 0.1 g of potassium iodide and 90 g of K, N-dimethylformamide are stirred and heated at SO-HY C. After cooling, the reaction mixture is added to water. After stirring, the product is filtered off and crystallized from N, N-dimethyl form, yielding 4.8 g (39%) (6-fluoro 1,2-benzisoxazole-3-yl) -1-piperidinip ethylZ-2 5 4 ( 1H, 3N) -quinozolindione so pl. 253.4 ° C (compound 12).
PRI me R 4. A mixture of 7.4 g of 6- (2-bromoethyl) -3,7-dimethyl-5H-thiazole | .3,2-a pyrimidine-bromohydrate-5-one, 4.4 t 6 -fluoro-3- (4-piperidine 1) -1,2-benzoisoxazole, iO g sodium carbonate and 90 g M, L-dimethylformamide are stirred overnight at 80- 85.C After cooling, the reaction mixture is added to water. The product is filtered and purified by capillary chromatography on silica gel using a mixture of trichloromethane and metha-NOL (95: 5 by volume) as eluent. The pure fractions are collected and the eluent is evaporated. 2-Propanol is added to the residue. The product is filtered off and dried, yielding 5.3 g (62%) of 6-2-4- (6-fluoro-1,2-benzisoxol-3-yl) -1-piperidiyl3, 7-dimeth-5H-thiazole C3 , 2-a pyrimidine-5-one, so pl. 231.0 ° C (compound 13).
Similarly, also receive:
(6-fluoro-1,2-benzisoxazol-3-ip) -1-piperidinyl ethyl -2,3-dihydro-7-methyl-5K-thiazole 3,2-a gtirimkdin 5-one, m.p. 135.0 C (compound 14);
4- (6-fluoro-i, 2-benzisoxazole 3-yl) -1-piperidinylZ zhyl-3, 4-digndro-8-methyl-2H, 6H-pyrimndo 2, -1533 thiazin-6-one, t .pl. 169, (compound 15);
4- (1, 2-benzisoxazol-3-yl) - -piperidinyl3, 3-dihydro-7-methyl-5N thiazole GZ, 2-aJ pyrimI d w-5- he, so pl. 5455 ° C (compound 16);
(6-fluoro-1 52-benzisothiazole 3-yl) -1-piper.idish ethyl ethyl-6,7,859-tetra-hydro-2-methyl-4H-pyrido fl, 2-aJ pyrimidalk-4-one ( compound 17);
3- 2-G4- (6-fluoro-, 2-benzisoxazole 3-yl) -1-piperidinyl ethylZ-253-dihydro-2-thioxo-4 (IN) -quinazolinone (compound 18).
Similarly, described fy in the example and using the appropriate starting materials, compounds are prepared:
6,7,8,9-tetrahydro-3 G2-4- (6-met-, yksi-1,2-benzisoxazol-3-yl) -1-piperidine 1-shtyl -2-meth-yl-4H pyrido C, 2-a pyrimidin-4-it, so pl. 148.6 ° C;
.. 3,4-dihydro-7 p- 4- (6-methoxy-1,2-benzisoxazol-3-yl) - 1-piperidinium. P-13-metip-2H, bN-pyrimido | 2.1 -bJ 3 thiazin-bb, mp, 174.6 ° C;
2, 3-dihydro-6-G2-4- (6-methoxy-1,2-benzisoxazol-3 yl) -piperidyl
ethyl-methyl-5H-thiazolo 3,2-aZ pyri-MIDIN-5-OH5 m.p. 175.9 ° C;
7-chloro-3-2- 4- (6-fluoro-1,2-benz-isoxazole 3-yl) - -piperidinyl | ethyl -2-methyl-4I-pyrido Cl, 2-a pyrimidine-4-one, so pl. 203.8 ° C;
(6-fluoro-1,2-benzisoxazol-3-yl) -1-piperidinyl Zethyl-25b, 8-trimethyl 4H-pyrido p, 2-a pyrimidin-4-one, m.p. 155.1 ° C;
4- (6-fluoro-1,2-benzisoxazol-3-yl) - 1-sh-shridinyl prop1ot -2-methyl-4H-pyrido l, 2-a1-pyrimidin-4-one, m.p. 141.3 ° C;
(6-fluoro-1,2-benzisoxazol-3-yl) -1-mnchideridiot from ethyl-6-methyl-2.4 (1H, 3N) -hinazolinedione, m.p. 224.5 ° C;
4- (6-fluoro-1,2-benzisoxazol-3-yl) -1-piperidinyl 1 tyl 1-2,6-dimethyl-4H-pyrido l, 2-a pyrimidine-4-one, so pl. 193.6 C;
(6-fluoro-1,2-5 benzoxazole-3-yl) -l-piperidinylJ, 7.
experimental techniques. danshl 11e 1 c. tab. one .
I, the combined test on. rats apomorphine (apo), triptag-gana
8,9-tetrahydro-2-metsh1-4H-pyrido
., 2-gshrimidin-4-one, t pl. 155.3 C;
3-.3-4- {6-fluoro-, 2-b. Benzisoxazol-3 yl) -l piperidinyl propylJ | -254- (1H, 3N) -quinazolindione, t, pl „197.7 ° С; (THREE) and norepinephria (NRA).
3 H- 4- (6-fluoro-S 2 benzisox-) - 1-piperidine {propyl-b, 7sB99-tetrahydro 2-methyl-4H-pyrido
The experimental belly 1s used in this test are 5 adult males.
/ с о ь: ifci 1 p cti imr -
, 2-a pyrimidin-4-one, mp 133.1 ° C; 10 1 Wistav line weight (weight 240 ± 10 g).
(6-fluoro-1,2-benzisocol sol-3-yl) -l-piperidinylJ ethyl -2J3-dihydro-7-methyl-5H-thiazol, 2-a pyrimidine-5-one, t, pl, 09.1 ° C;
(5-fluoro-1j2-6eH3H30Kca-sozo (-3-yl) -1-piperidinyl ethyl-3,4-dihydro-8-methyl-2H, bH-pyrimido 2, 1 bj 15Z-thiazin-b-one, t , pl. 108s3 ° C;
(6-fluoro-152-benzisoxazole) After fasting for the knives, 1 ml / 100 g of an aqueous solution of the test compound was subcutaneously injected into animals (time zero) and placed in 15 individual dp cells after observation, 30 minutes later (time 30 minutes) were intravenously administered 1, 25 mg / kg apomorphing hydrochloride and a rat-sh are monitored for 1 hour to determine the presence of
I ((t-f- J tlJ.-J - - 4 -,
) -piperidl butyl -2-methyu1-20 or the absence of the following left-4H-pyridoS1,2-a irimidin-4-one, t, caused by apomorphine:
, „1DP qOp. Excitation and stereotypical chewing ,,

(5-fluoro-152-benzisoxazole- At the end of this one-hour period, 3-yl) -1 - piperidnyl1ett 2-methyl-4H- (time 90 min) to the same animals in 1,2-a1-pyrimidin-4-one, m.p. 25 dates intravenously at 40 mg / kg THREE and
the presence of typical, triggered, bilateral tonic contractions is observed. Two hours after the pretreatment 30 (time 120 min), 1.25 mg / kg NOR and IV were intravenously administered to the same animals.
158.0 Cc
According to the procedure described in Example 1, but using the corresponding starting materials, the compounds were also obtained;
7 bromo-3-C2- 4- (6-fluoro-1., 2-benz-isoxazol-3-yl) -1-piperidinylDethyl -2-methyl-4H-pyridoC152 and 3 pyrimidine-4-oHs mp 185j9 C ;
3-G2-4- (6-fluoro-152-b-enzisoxazol-35) -1-piperidinylZ ethyl -2,3-di-HYDRO-2-TIOXO-4 (1H) -quinazolinone; mp 198.1 C;
(6-fluoro-152-benzisoxazole-3-1-sh) -piperidinylbutyl -2.4 (W, 3N) -quinazolinedione, m.p. 170.7 C;
3-t2-t4- (6-fluoro-1,2-benzisoxazole-3-cl) -1-pippvridinyl ethyl-6-ox-254- (1H, 3N) -quinazolinedione 5 Topl, 290 C;
(6-fluoro-1,2-benzisoxazol-3-yl) -1-piperidinyl ethyl-6-met-hydroxy-2, p4- (1H, 3N) -quinazolinedione, t „pl. .
over a period of time for up to 60 minutes, a possible death is observed.
In tab. 1 given the ED values for
compounds of general formula (I). In this case, the value is a dose of which prevents the appearance in 50% of animals of the effects, 40 caused by the action of ALO, TRI or HORO.
Ii. Testing the effects of ALO on dogs (APO-dog).
The compounds listed in Table 1 were administered subcutaneously to 6 dogs of the breed 45 beagle with various doses and an hour later the animals were administered a standard dose of 0.31 mg / kg (subcutaneously) APO.
In this case, ED is a dose that prevents 50 of vomiting in 50% of animals.
The activity of compounds (I) as psychotic agents becomes apparent from experimental data obtained from at least two different trials; mixed apomorphine-, tript.amin- and norepinephrine rat tests and apohrphine test on dogs. The tests are carried out following the indicated
experimental techniques. danshl 11e 1 c. tab. one .
I, Combined test on rats apomorphine (APO), tryptagana
(THREE) and norepinephria (NRA).
(THREE) and norepinephria (NRA).
The experimental belly 1s used in this test are 5 adult males.
-
1 Wistav line weight (weight 240 ± 10 g).
1 Wistav line weight (weight 240 ± 10 g).
After fasting for the knives, animals were subcutaneously injected with 1 ml / 100 g of an aqueous solution of the test compound (time zero) and placed in separate cells for observation. After 30 minutes (time 30 minutes) 1.25 mg / kg apomorphine hydrochloride was administered intravenously the rat-sh is monitored for 1 h to determine the presence of
-,
for a period of up to 60 minutes, a possible death is observed.
In tab. 1 given the ED values for
compounds of general formula (I). In this case, the value is a dose of which prevents the appearance in 50% of animals of the effects caused by the action of ALO, TRI or HORO.
Ii. Testing the effects of ALO on dogs (APO-dog).
The compounds listed in Table 1 were administered subcutaneously to 6 beagle breed dogs with various doses and an hour later an animal was given a standard dose of 0.31 mg / kg (subcutaneously) APO.
In this case, ED is a dose that prevents vomiting in 50% of animals.
Toxicological data.
Test compounds were administered to rats at different doses. LD was determined by the dose that caused the death of 50% of experimental animals. Compound (I), rats, mg / kg: by itself: when injected into the stomach 113; intravenous 34.3, females: when administered to the stomach 34.3; intravenously 35, -A.
In tab. 2 shows the ED values of the tested coupled. In these
In experiments, the ED value indicates the dose at which 50% of the animals did not have vomiting.
Given in Table. 2 BBOpflT compounds, orally or subcutaneously to dogs, a breed of short legged dogs in various doses, after 4 or 16 hours, dogs are given (subcutaneously) a standard dose of 0.31 mg / kg apomorphine.
Comparative data of compounds are given in table. 3 and 4.

权利要求:
Claims (1)
[1]
Invention Formula
The method of obtaining 1,2-benzisooxazolyl-3 or 1,2-bsnizo-thiazolyl-3 derivatives of the general formula
P.
- hydrogen, halogen, hydroxyl
or methoxy;
- hydrogen or halogen; JQ
- oxygen or sulfur; - C, 2-C4-alkylene;
- radical of general formula
n
35
Kh
.
- oxygen or sulfur; 40
- hydrogen, hydroxy. C, -C-alk-hydroxy or C-Cc-alkyl;
R4. hydrogen, halogen, or Q - radical
/
M
ABOUT
A-, where R 5 is hydrogen api C, is C-anKi-ui;
Z S-, or
where Rg and R7 independently of each other are hydrogen si-C4-alkyl;
Cj -C-alkyl or -, where Rg and R are non-dependent each other
from a friend is hydrogen, C-Cfalkyl or halogen,
or their st. reoizonerov or their acid additive salts, about tl and h; i-y i and the fact that the compound of
Q - Alk - W,
where W is halogen;
Q and Alk have the indicated value, are reacted with piperidine of the general formula
„
HHQLlIbLp
where R, and H, 2 are the indicated values, in an inert solvent, the desired product is isolated in free form, either as an acid addition salt or a stereoisomer.
0.08
0.08
T a
persons
a 1
0.16
146841910
Continuation of table 1
ABOUT
Z CHS ..
k Nyl-CHrCH.r O-C-OF
ABOUT
-S-CH -CH, j-0.31
-S-CH, -CH, .- CH ,, - 0.31
Table 3
ABOUT
..
0.160.63 0.03
0.631.25 0.03
.Z.N. сНзN
A lt / -CH2-CHr O
I sn,
14-S-CH, -CH, -0.020,0050,310,004
15-S-CHj-CH, -CH, 0.080.01 x 0.310.015
X

类似技术:

公开号 | 公开日 | 专利标题

SU1468419A3|1989-03-23|Method of producing derivatives of 1,2-benzisoxazolyl-3, or 1,2-benzisothiazolyl-3 or stereosiomers thereof or acid-additive salts thereof

KR100341683B1|2002-11-30|Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity

SU1138032A3|1985-01-30|Method of obtaining derivatives of bicyclic pyramidine-5-on or their salts with pharmaceutically acceptable acids or their cis- or trans-isomers

JP4734119B2|2011-07-27|Indazole compounds and their pharmaceutical uses

CA2598216C|2014-04-08|Androgen receptor modulator compounds and methods

PT92935B|1995-12-29|METHOD FOR PREPARING A PYRAZOLE-PYRIDINE COMPOUND AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT

US5001130A|1991-03-19|Psychotropic heterobicycloalkylpiperazine derivatives

CZ417991A3|1993-04-14|Annellated indole derivatives

JP2013509382A|2013-03-14|Nitrogen-containing heteroaryl derivatives as JAK3 kinase inhibitors

NZ225706A|1990-04-26|2-|methyl)-1,2,3,4-tetrahydro-9h-pyrido| indole derivatives and their preparation

FI75160B|1988-01-29|FOERFARANDE FOER FRAMSTAELLNING AV TERAPEUTISKT ANVAENDBARA PIPERIDYLIDENDERIVAT.

RU2037495C1|1995-06-19|2,9-disubstituted 4h-pyrido-|-pyrimidine-4-ones and antipsychotic composition

KR830000026B1|1983-01-29|Process for preparing tricyclic ortho-fused heterocyclic compounds

EP0808313B1|2003-08-13|Antipsychotic 4-|-1-substituted piperidine derivatives

JP6585718B2|2019-10-02|New benzimidazole derivatives as antihistamines

CS207617B2|1981-08-31|Method of making the new derivatives of 5,11-dihydro-6h-pyrido-2,3-b 1,4 benzodiazepin-6-one

HU0003624A2|2001-04-28|1,2,3,4-tetrahydro-benzofuro[3,2-c]pyridine derivatives, pharmaceutical compositions containing them and process for their preparation

CS29792A3|1992-08-12|N-|heteroaryl-8-azabicyclo/3.2.1/ octanes, intermediatesthereof and process of their preparation and use as medicaments

EP0607163B1|1996-12-11|NEUROLEPTIC 2-SUBSTITUTED PERHYDRO-1-H-PYRIDO[1,2-a]PYRAZINES

HU191076B|1987-01-28|Process for producing 6-fluoro/-3-|-propyl/- 1,2-benzisoxazol derivatives and phrmaceiutical compositions containing them

DK169721B1|1995-01-23|Substituted Spiro-Pyridine Derivatives, Pharmaceutical Preparations Containing Them, and Process for Preparing Such Derivatives

KR100309215B1|2001-12-28|Pyridineiminyl-1,2-benzisoxazole and -benzisothiazole as antipsychotics

BR112020018983A2|2020-12-29|OXADIAZOLE TRANSITORY POTENTIAL RECEPTOR CHANNEL INHIBITORS

RU2057754C1|1996-04-10|Heterocyclic compounds or their acid-additive salts

BRPI0813777B1|2020-12-08|compound, pharmaceutical composition, and, use of a compound

同族专利:

公开号 | 公开日

JPH0613511B2|1994-02-23|

EP0196132A3|1988-01-20|

CY1801A|1995-02-17|

US4804663A|1989-02-14|

DK143986A|1986-09-28|

HK108794A|1994-10-14|

DK168537B1|1994-04-18|

EP0196132A2|1986-10-01|

AU579232B2|1988-11-17|

AU5529786A|1986-10-02|

EP0196132B1|1992-08-12|

SG119294G|1995-03-17|

DK143986D0|1986-03-26|

BG60432B2|1995-03-31|

IE58388B1|1993-09-08|

IE860801L|1986-09-27|

CA1256867A|1989-07-04|

NL940006I1|1994-05-16|

CN86101906A|1986-10-01|

CN1022566C|1993-10-27|

LU88576I2|1995-03-21|

NL940006I2|1999-09-01|

JPS61221186A|1986-10-01|

引用文献:

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

US4128641A|1975-07-31|1978-12-05|Hzi Research Center Inc.|Tetracyclic psychotropic drug|

US4335127A|1979-01-08|1982-06-15|Janssen Pharmaceutica, N.V.|Piperidinylalkyl quinazoline compounds, composition and method of use|

US4342870A|1980-03-28|1982-08-03|Janssen Pharmaceutica N.V.|Novel 3--4H-pyrido[1,2-a]pyrimidin-4-one derivatives|

US4337261A|1980-07-28|1982-06-29|Hoechst-Roussel Pharmaceuticals Inc.|phenoxyacetic acids as diuretics|

US4443451A|1981-07-15|1984-04-17|Janssen Pharmaceutica N.V.|Bicyclic pyrimidin-5-one derivatives|

US4529727A|1982-04-21|1985-07-16|Janssen Pharmaceutical, N.V.|Pyrimido[2,1-b][1,3]-thiazines|

WO1983000520A1|1981-07-30|1983-02-17|Dow Corning|Silicone elastomer based roofing system|

US4352811A|1981-11-12|1982-10-05|Hoechst-Roussel Pharmaceuticals Inc.|3--1,2-benzisoxazoles|

US4485107A|1982-11-01|1984-11-27|Janssen Pharmaceutica N.V.|[[Bismethylene]-1-piperidinyl]alkyl-pyrimidinones|

US4458076A|1983-05-31|1984-07-03|Hoechst-Roussel Pharmaceuticals|3--1,2-benzisothiazoles|

EP0144101B1|1983-11-30|1991-02-06|Janssen Pharmaceutica N.V.|Bicyclic heterocyclyl containing n--4-piperidinamines|

PH23995A|1984-01-09|1990-02-09|Janssen Pharmaceutica Nv|4-methyl and hetero)piperidines|

US4665075A|1984-12-05|1987-05-12|Janssen Pharmaceutica N.V.|Derivatives of hydroxy- or amino-substituted quinazolines|

US4689330A|1985-04-15|1987-08-25|Janssen Pharmaceutica N.V.|Antidepressive substituted N-[alkyl] bicyclic condensed oxazol- and thiazolamines|

HUT43600A|1985-06-22|1987-11-30|Sandoz Ag|Process for production of new thiazole derivatives and medical compound containing those|CA1335289C|1987-10-26|1995-04-18|Fujio Antoku|Piperidinyl benzisoxazole derivatives, their production and pharmaceutical use|

US5116970A|1988-02-18|1992-05-26|New James S|Psychotropic heterobicycloalkylpiperazine derivatives: 2. fused pyridazinones|

US5001130A|1988-02-18|1991-03-19|Bristol-Myers Company|Psychotropic heterobicycloalkylpiperazine derivatives|

GR1000667B|1988-03-21|1992-09-25|Janssen Pharmaceutica Nv|Process of preparing 3-piperidinyl-1,2- benzisoxazoles|

US5015740A|1988-08-05|1991-05-14|Janssen Pharmaceutica N.V.|Antipsychotic 3-piperazinylbenzazole derivatives|

US4957916A|1988-08-05|1990-09-18|Janssen Pharmaceutica N.V.|Antipsychotic 3-piperazinylbenzazole derivatives|

NZ230045A|1988-08-05|1990-11-27|Janssen Pharmaceutica Nv|3-piperazinylbenzazole derivatives and pharmaceutical compositions|

US5196425A|1988-09-02|1993-03-23|Janssen Pharmaceutica N.V.|Antihypertensive 3-piperidinyl-indazole derivatives|

IL90879D0|1988-09-02|1990-02-09|Janssen Pharmaceutica Nv|3-piperidinyl-indazole derivatives,their preparation and antihypertensive compositions containing them|

US5321028A|1988-09-02|1994-06-14|Janssen Pharmaceutica N.V.|Antihypertensive 3-piperidinyl-indazole derivatives|

US5158952A|1988-11-07|1992-10-27|Janssen Pharmaceutica N.V.|3-[2-[4--1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use|

CA2000786C|1988-11-07|1999-01-26|Cornelus G. M. Janssen|3-piperidinyl-1,2-benzisoxazoles|

US5254556A|1988-11-07|1993-10-19|Janssen Pharmaceutica N.V.|3-piperidinyl-1,2-benzisoxazoles|

WO1990006303A1|1988-12-02|1990-06-14|Pfizer Inc.|Arylpiperidine derivatives|

FR2641278B1|1989-01-05|1991-03-22|Lipha|PIPERIDINES, METHODS OF PREPARATION AND MEDICAMENTS CONTAINING THEM|

GB8900382D0|1989-01-09|1989-03-08|Janssen Pharmaceutica Nv|2-aminopyrimidinone derivatives|

US5256659A|1989-01-09|1993-10-26|Janssen Pharmaceutica N.V.|2-aminopyrimidinone derivatives|

FR2654104B1|1989-11-07|1992-01-03|Adir|NOVEL 1,2-BENZISOXAZOLE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.|

GB9008850D0|1990-04-19|1990-06-13|Janssen Pharmaceutica Nv|Novel 2,9-disubstituted-4h-pyridolpyrimidin-4-ones|

US5075315A|1990-05-17|1991-12-24|Mcneilab, Inc.|Antipsychotic hexahydro-2H-indeno[1,2-c]pyridine derivatives|

US6004980A|1990-06-01|1999-12-21|Merrell Pharmaceuticals, Inc.|-α--1-[2-ethyl]-4-piperidinemethanol|

ES2067937T3|1990-06-01|1995-04-01|Merrell Dow Pharma| - ALPHA--1-ETIL) -4-PIPERIDINAMETANOL.|

US5147881A|1990-11-14|1992-09-15|Pfizer Inc|4-piperidine antipsychotic agents|

FR2671350B1|1991-01-08|1993-02-26|

WO1993004063A1|1991-08-22|1993-03-04|Yoshitomi Pharmaceutical Industries, Ltd.|Benzisoxazole compound and use thereof|

US5532243A|1992-02-14|1996-07-02|The Dupont Merck Pharmaceutical Company|Antipsychotic nitrogen-containing bicyclic compounds|

DE4243287A1|1992-06-19|1993-12-23|Basf Ag|N-substituted azabicycloheptane derivatives, their preparation and use|

PT672043E|1992-07-13|2001-11-30|Janssen Pharmaceutica Nv|NEW DERIVATIVES OF 4-PIPERIDINYL AND 4-PIPERIDINYL AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM|

TW376319B|1993-04-28|1999-12-11|Janssen Pharmaceutica Nv|Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine|

DE4338396A1|1993-11-10|1995-05-11|Basf Ag|N-Substituted azabicycloalkane derivatives, their preparation and use|

DK0729357T3|1993-11-19|2005-06-06|Janssen Pharmaceutica Nv|Microencapsulated 1,2-benzazoles|

AU687940B2|1993-11-23|1998-03-05|Janssen Pharmaceutica N.V.|Novel 9-hydroxy-pyridopyrimidin-4-one ether derivatives|

ES2074966B1|1994-02-11|1996-06-16|Vita Invest Sa|PROCEDURE FOR OBTAINING 3-ISOXAZOL-3-IL) PIPERIDIN-1-IL) -ETIL) -2-METHYL-6,7,8,9- TETRAHIDRO-4H-PIRIDO-PIRIMIDIN-4-ONA.|

ES2085234B1|1994-02-24|1997-01-16|Vita Invest Sa|ACTIVE AGENT ON THE CENTRAL NERVOUS SYSTEM, PROCEDURE FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT.|

CA2144669A1|1994-03-29|1995-09-30|Kozo Akasaka|Biphenyl derivatives|

WO1996016968A1|1994-11-25|1996-06-06|Meiji Seika Kabushiki Kaisha|Bicyclic thiazole compound|

JP3274579B2|1995-01-12|2002-04-15|住友製薬株式会社|Agent for treating psychiatric symptoms associated with cerebrovascular disorders|

DE69635798T2|1995-02-28|2006-08-17|H. Lundbeck A/S|4-AMINOTETRAHYDROBENZISOXAZOLE OR ISOTHIAZOLE|

TW592729B|1995-04-06|2004-06-21|Janssen Pharmaceutica Nv|Rate-controlled transdermal administration of risperidone|

KR960042947A|1995-05-09|1996-12-21|김주용|Highly integrated semiconductor device and local connection method|

ES2097093B1|1995-05-26|1998-01-16|Ferrer Int|NEW COMPOUNDS DERIVED FROM 5H-TIAZOLOPIRIMIDIN-5-ONA.|

US6028083A|1997-07-25|2000-02-22|Hoechst Marion Roussel, Inc.|Esters of -α--1-[2- ethyl]-4-piperidinemethanol|

AP1228A|1997-11-17|2003-11-12|Janssen Pharmaceutica Nv|Aqueous suspensions of submicron 9-hydroxyrisperidone fatty acid esters.|

ES2141671B1|1997-12-26|2001-01-01|Vita Invest Sa|ACTIVE PYRIMIDINIC COMPOUND ON THE CENTRAL NERVOUS SYSTEM, PROCEDURE FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT.|

FR2802101B1|1999-12-10|2003-02-28|Aventis Pharma Sa|COMBINATION OF CYMEMAZINE AND AN ATYPICAL NEUROLEPTIC|

US6770478B2|2000-02-10|2004-08-03|The Regents Of The University Of California|Erythrocytic cells and method for preserving cells|

EP1280804B1|2000-05-05|2004-04-14|RPG Life Sciences Limited|A process for the preparation of anti-psychotic 3- 2- 4--1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4h-pyrido 1,2,-a]pyrimidin-4-one|

US6264987B1|2000-05-19|2001-07-24|Alkermes Controlled Therapeutics Inc. Ii|Method for preparing microparticles having a selected polymer molecular weight|

US6495164B1|2000-05-25|2002-12-17|Alkermes Controlled Therapeutics, Inc. I|Preparation of injectable suspensions having improved injectability|

US20040023951A1|2001-06-18|2004-02-05|Bymaster Franklin Porter|Combination therapy for treatment of psychoses|

WO2002012200A1|2000-08-08|2002-02-14|Teva Pharmaceutical Industries Ltd.|Preparation of risperidone|

EP1783118B1|2000-08-14|2008-07-16|Teva Pharmaceutical Industries Ltd.|Preparation of risperidone|

DE60134899D1|2000-08-14|2008-08-28|Teva Pharma|Preparation of risperidone|

DE10129320A1|2001-06-19|2003-04-10|Norbert Mueller|Use of cyclooxygenase-2 inhibitor in the preparation of a medicament for treating psychiatric disorders e.g. schizophrenia|

US6730772B2|2001-06-22|2004-05-04|Venkatram P. Shastri|Degradable polymers from derivatized ring-opened epoxides|

ES2370634T3|2001-08-31|2011-12-21|Novartis Ag|OPTICAL ISOMERS OF AN ILOPERIDONE METABOLITE.|

US6824822B2|2001-08-31|2004-11-30|Alkermes Controlled Therapeutics Inc. Ii|Residual solvent extraction method and microparticles produced thereby|

HU227118B1|2001-11-13|2010-07-28|Egis Gyogyszergyar Nyilvanosan|Process for the preparation of 3-{2-[4--1-piperidinyl]-ethyl}-6,7,8,9-tetrahydro-2-methyl-4h-pyrido[1,2-a]pyrimidin-4-one|

CA2468972A1|2001-12-10|2003-07-03|Novartis Ag|Methods of treating psychosis and schizophrenia based on a polymorphism in the cntf gene|

ES2197801B1|2002-03-05|2005-03-16|Ferrer Internacional,S.A|PROCEDURE FOR OBTAINING THE 3-ISOXAZOL-3-IL) PIPERIDIN-1-IL) -ETIL) -2-METHYL-6,7,8,9- TETRAHIDRO-4H-PIRIDO-PIRIMIDIN-4-ONA.|

WO2004009591A1|2002-07-22|2004-01-29|Aurobindo Pharma Ltd.|A process for the preparation of antipsychotic risperidone|

US20050232995A1|2002-07-29|2005-10-20|Yam Nyomi V|Methods and dosage forms for controlled delivery of paliperidone and risperidone|

US20060148826A1|2002-08-23|2006-07-06|Ashish Gogia|Stable aqueous solutions of risperidone and methods for their preparation|

AU2003256006A1|2002-08-30|2004-03-19|Sunil Sadanand Nadkarni|Improved process for preparation of risperidone|

KR20040025224A|2002-09-18|2004-03-24|주식회사 대웅|2-acetaldehyde and preparation process of the same|

KR20040034996A|2002-10-18|2004-04-29|한미약품 주식회사|Improved method for the preparation of risperidone|

US6800663B2|2002-10-18|2004-10-05|Alkermes Controlled Therapeutics Inc. Ii,|Crosslinked hydrogel copolymers|

EP1560814A1|2002-11-13|2005-08-10|Synthon B.V.|Process for making risperidone and intermediates therefor|

DE10259382A1|2002-12-18|2004-07-01|Abbott Gmbh & Co. Kg|3-Substituted 3,4-dihydro-thieno [2,3-d] pyrimidin-4-one derivatives, their preparation and use|

US7658998B2|2003-01-22|2010-02-09|Alkermes Controlled Therapeutics, Inc.|Method of preparing sustained release microparticles|

WO2004094415A1|2003-04-22|2004-11-04|Synthon B.V.|Risperidone monohydrochloride|

EP1633400A2|2003-05-16|2006-03-15|Pfizer Products Inc.|Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines|

US20050036977A1|2003-08-11|2005-02-17|Dilip Gole|Taste-masked resinate and preparation thereof|

ZA200603113B|2003-09-26|2007-08-29|Jubilant Organosys Ltd|Process for the preparation of risperidone|

GB0322994D0|2003-10-01|2003-11-05|Novartis Ag|Organic compounds|

NZ546063A|2003-10-23|2009-05-31|Otsuka Pharma Co Ltd|Controlled release sterile injectable aripiprazole -1-piperazinyl]-butoxy]-3,4-dihydro-2-quinolinone) formulation and method|

GB0326148D0|2003-11-10|2003-12-17|Lilly Co Eli|Morpholine derivatives|

WO2005051919A1|2003-11-26|2005-06-09|Pfizer Products Inc.|Aminopyrazole derivatives as gsk-3 inhibitors|

EP1737473A4|2004-04-19|2009-08-26|Noven Therapeutics Llc|Lithium combinations, and uses related thereto|

WO2005107808A2|2004-05-11|2005-11-17|Pfizer Products Inc.|Combination of atypical antipsychotics and 5-ht1b receptor antagonists|

MY147767A|2004-06-16|2013-01-31|Janssen Pharmaceutica Nv|Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders|

AR049646A1|2004-06-16|2006-08-23|Janssen Pharmaceutica Nv|USEFUL SULFAMATE AND SULFAMIDE DERIVATIVES FOR THE TREATMENT OF EPILEPSY AND RELATED DISORDERS|

US20060004199A1|2004-07-01|2006-01-05|Dr. Reddy's Laboratories Limited|Process for the preparation of pure 3-[2-[4--1-piperidinyl]-ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido [1,2-a] pyrimidin-4-one|

TW200616608A|2004-07-09|2006-06-01|Forest Laboratories|Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients|

AT400565T|2004-08-24|2008-07-15|Janssen Pharmaceutica Nv|NEW BENZO-CONDENSED HETEROARYLSULFAMID DERIVATIVES SUITABLE AS ANTICONVULSIVE AGENTS|

ES2317138T3|2004-11-22|2009-04-16|Hisamitsu Pharmaceutical Co., Inc.|TRANSDERMAL PATCH THAT INCLUDES AN AGENT OF DIMINUTION OF THE FUSION POINT.|

EP1863485A2|2005-03-18|2007-12-12|Abbott Laboratories|Alpha7 neuronal nicotinic receptor ligand and antipsychotic compositions|

MX2007013026A|2005-04-22|2008-01-11|Wyeth Corp|Therapeutic combinations for the treatment or prevention of psychotic disorders.|

WO2006127184A1|2005-05-20|2006-11-30|Janssen Pharmaceutica N.V.|Process for preparation of sulfamide derivatives|

WO2006129160A2|2005-06-01|2006-12-07|Aurobindo Pharma Limited|Stable aqueous oral solution of risperidone|

WO2007035348A2|2005-09-15|2007-03-29|Elan Pharma International, Limited|Nanoparticulate aripiprazole formulations|

US20070134310A1|2005-09-23|2007-06-14|Nedberge Diane E|Transdermal risperidone delivery system|

US8852638B2|2005-09-30|2014-10-07|Durect Corporation|Sustained release small molecule drug formulation|

US20070155824A1|2005-12-19|2007-07-05|Smith-Swintosky Virginia L|Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis|

US20070155823A1|2005-12-19|2007-07-05|Smith-Swintosky Virginia L|Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents|

US8716231B2|2005-12-19|2014-05-06|Janssen Pharmaceutica Nv|Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain|

US20070155827A1|2005-12-19|2007-07-05|Smith-Swintosky Virginia L|Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression|

US8937096B2|2005-12-19|2015-01-20|Janssen Pharmaceutica Nv|Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder|

US8492431B2|2005-12-19|2013-07-23|Janssen Pharmaceutica, N.V.|Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity|

US8497298B2|2005-12-19|2013-07-30|Janssen Pharmaceutica Nv|Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels|

US8691867B2|2005-12-19|2014-04-08|Janssen Pharmaceutica Nv|Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction|

US20070191450A1|2006-02-15|2007-08-16|Smith-Swintosky Virginia L|Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Mania and Bipolar Disorder|

US20070191460A1|2006-02-15|2007-08-16|Smith-Swintosky Virginia L|Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Disease Modification / Epileptogenesis|

GB0603087D0|2006-02-15|2006-03-29|Glaxo Group Ltd|Novel use|

US20070191474A1|2006-02-15|2007-08-16|Smith-Swintosky Virginia L|Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine|

US20070191451A1|2006-02-15|2007-08-16|Smith-Swintosky Virginia L|Use of benzo-heteroaryl sulfamide derivatives as neuroprotective agents|

JP4922657B2|2006-05-09|2012-04-25|高田製薬株式会社|Risperidone oral solution|

JP2009537635A|2006-05-19|2009-10-29|ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ|Co-therapy for treatment of hemorrhoids|

US20090306137A1|2006-05-22|2009-12-10|Wolfgang Curt D|Treatment for depressive disorders|

AT523602T|2006-06-12|2011-09-15|Hadasit Med Res Service|ANTI-SYMPTOMS INDUCED BY EXTRACYRAMIDAL SYMPTOMS ASSOCIATED RGS2 GENOTYPES|

US20080004260A1|2006-06-29|2008-01-03|Transcept Pharmaceuticals, Inc.|Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions|

EP1945640A2|2006-08-14|2008-07-23|Teva Pharmaceutical Industries Ltd.|Process for the synthesis of 9-hydroxy risperidone |

WO2008047340A1|2006-10-19|2008-04-24|Mor Research Applications Ltd.|Combined therapies of antipsychotic drugs and tetracyclines in the treatment of psychiatric disorders|

WO2008087557A2|2007-01-08|2008-07-24|Actavis Group Ptc Ehf|An improved process for preparation of 9-hydroxy-3-- 2-methyl-4h-pyrido[1,2-a]pyrimidin-4-one hydrochloride|

CN101245065B|2007-02-14|2010-05-19|江苏恩华药业股份有限公司|Method for producing benzo isoxazole derivative and its intermediate|

JP4941977B2|2007-04-11|2012-05-30|大蔵製薬株式会社|Oral jelly-like pharmaceutical composition of benzisoxazole derivative|

JP2010531807A|2007-05-25|2010-09-30|トルマーセラピューティクス，インコーポレイテッド|Slow-broadcast formulation of risperidone compound|

NZ582415A|2007-07-31|2012-05-25|Otsuka Pharma Co Ltd|Methods for producing aripiprazole suspension and freeze-dried formulation|

AT530170T|2007-08-21|2011-11-15|Teva Pharma|PALIPERIDONE FORMULATION WITH DELAYED RELEASE|

WO2009056990A2|2007-08-21|2009-05-07|Actavis Group Ptc Ehf|Paliperidone polymorphs|

US7776866B2|2007-09-15|2010-08-17|Protia, Llc|Deuterium-enriched risperidone|

US7977480B2|2007-12-10|2011-07-12|Synthon Bv|Synthesis of paliperidone|

EP2234617B1|2007-12-19|2021-03-31|Janssen Pharmaceutica NV|Dosing regimen associated with long acting injectable paliperidone esters|

US20090247617A1|2008-03-26|2009-10-01|Abdel-Magid Ahmed F|Process for the preparation of benzo-fused heteroaryl sulfamates|

US20090247553A1|2008-03-27|2009-10-01|Actavis Group Ptc Ehf|Highly Pure Paliperidone or a Pharmaceutically Acceptable Salt Thereof Substantially Free of Keto Impurity|

WO2009128058A1|2008-04-18|2009-10-22|UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al|Psycho-pharmaceuticals|

US8481729B2|2008-06-16|2013-07-09|Msn Laboratories Limited|Processes for the preparation of paliperidone|

EP2340246A2|2008-06-23|2011-07-06|Janssen Pharmaceutica, N.V.|Crystalline form of --n--sulfamide|

JP2011526881A|2008-06-25|2011-10-20|ファイザー・インク|Diaryl compounds and their use|

EP2138495A1|2008-06-26|2009-12-30|sanofi-aventis|Substituted pyrimido[2,1-a]isoquinolin-4-one derivatives|

EP2138494A1|2008-06-26|2009-12-30|Sanofi-Aventis|Substituted alkyl pyrimidin-4-one derivatives|

EP2138488A1|2008-06-26|2009-12-30|sanofi-aventis|4--1H-[1,3,5]triazin-2-one derivatives as GSK3-beta inhibitors for the treatment of neurodegenerative diseases|

EP2138485A1|2008-06-26|2009-12-30|sanofi-aventis|Substituted N-Oxide pyrazine derivatives|

EP2138493A1|2008-06-26|2009-12-30|Sanofi-Aventis|Substituted pyrimidone derivatives|

EP2138498A1|2008-06-26|2009-12-30|sanofi-aventis|Substituted tricyclic derivatives against neurodegenerative diseases|

EP2138492A1|2008-06-26|2009-12-30|Sanofi-Aventis|Substituted pyrimidin-4-one derivatives|

WO2010003703A2|2008-07-11|2010-01-14|Synthon B.V.|Paliperidone ketone|

US8815939B2|2008-07-22|2014-08-26|Janssen Pharmaceutica Nv|Substituted sulfamide derivatives|

EP2199293A1|2008-12-22|2010-06-23|Chemo Ibérica, S.A.|One-step process for preparing paliperidone and its oxalate salt|

US20100298397A1|2009-05-19|2010-11-25|Singh Nikhilesh N|Method of treatment of obsessive compulsive disorder with ondansetron|

US20120100188A1|2009-05-28|2012-04-26|Actavis Group Ptc Ehf|Solid state forms of paliperidone salts and process for the preparation thereof|

US8252801B1|2009-06-03|2012-08-28|Abbott Laboratories|Treatment of schizophrenia and related disorders|

AT544766T|2009-07-13|2012-02-15|Krka|PROCESS FOR SYNTHESIS OF PALIPERIDONE|

US20120164188A1|2009-09-10|2012-06-28|Actavis Group Ptc Ehf|Paliperidone or a pharmaceutically acceptable salt thereof substantially free of impurities|

JP6076740B2|2010-01-07|2017-02-08|アルカーメスファーマアイルランドリミテッド|Quaternary ammonium salt prodrug|

EP2547206B1|2010-03-15|2016-05-11|Inventia Healthcare Private Limited|Stabilized prolonged release pharmaceutical composition comprising atypical antipsychotic|

US9272044B2|2010-06-08|2016-03-01|Indivior Uk Limited|Injectable flowable composition buprenorphine|

GB2513060B|2010-06-08|2015-01-07|Rb Pharmaceuticals Ltd|Microparticle buprenorphine suspension|

US20130190299A1|2010-06-30|2013-07-25|Victoria Link Ltd.|Methods and compositions for treatment of multiple sclerosis|

DK2608670T3|2010-08-23|2019-02-11|Alkermes Pharma Ireland Ltd|METHOD OF TREATING ANTI-SOCIETY-INDICATED WEIGHT RISE|

WO2012035554A1|2010-09-14|2012-03-22|Megafine PharmaLtd.|An improved process for the preparation of highly pure paliperidone|

BR112013012062B1|2010-11-15|2020-06-02|Agenebio, Inc|COMPOSITE DERIVED FROM PYRIDAZINE OR PHARMACEUTICALLY ACCEPTABLE SALT, PHARMACEUTICAL COMPOSITION AND USE OF THE COMPOUND|

WO2012147035A1|2011-04-26|2012-11-01|Torrent Pharmaceuticals Limited|Acid addition salts of risperidone and pharmaceutical compositions thereof|

WO2013095314A1|2011-12-19|2013-06-27|Mahmut Bilgic|Pharmaceutical formulations comprising risperidone|

WO2013100876A1|2011-12-27|2013-07-04|Mahmut Bilgic|Risperidone formulations|

CA2882563A1|2012-08-21|2014-02-27|Eric Hryhorenko|Antibodies to risperidone haptens and use thereof|

WO2014031648A2|2012-08-21|2014-02-27|Ortho-Clinical Diagnostics, Inc|Antibodies to risperidone and use thereof|

WO2014031601A1|2012-08-21|2014-02-27|Janssen Pharmaceutica Nv|Haptens of risperidone and paliperidone|

JP2015529199A|2012-08-21|2015-10-05|オルソ−クリニカルダイアグノスティクス，インコーポレイティド|Antibodies against paliperidone hapten and use thereof|

CN104736561B|2012-08-21|2018-06-12|詹森药业有限公司|Antibody of Paliperidone and application thereof|

JP6538559B2|2012-09-28|2019-07-03|デルポー，インコーポレイティド|Device and method for sustained release of antipsychotic drug|

US20140206667A1|2012-11-14|2014-07-24|Michela Gallagher|Methods and compositions for treating schizophrenia|

CA2934553A1|2013-12-20|2015-06-25|Agenebio, Inc.|Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment|

GB201404139D0|2014-03-10|2014-04-23|Rb Pharmaceuticals Ltd|Sustained release buprenorphine solution formulations|

CA3015557C|2014-11-07|2019-07-16|Indivior Uk Limited|The use of sustained-release buprenorphine formulations for the treatment of pain or opioid use disorders|

CA2990004A1|2015-06-19|2016-12-22|Agenebio, Inc.|Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment|

AU2016372069A1|2015-12-17|2018-06-07|Saladax Biomedical Inc.|Antibodies to risperidone and use thereof|

US20180170941A1|2016-12-19|2018-06-21|Agenebio, Inc.|Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment|

US10646484B2|2017-06-16|2020-05-12|Indivior Uk Limited|Methods to treat opioid use disorder|

法律状态:

优先权:

申请号 | 申请日 | 专利标题

US71706785A| true| 1985-03-27|1985-03-27|

SG119294A|SG119294G|1985-03-27|1994-08-20|1,2-benzisoxazol-3-yl and 1,2-benzisothiazol-3-yl derivatives|LV920228A| LV5043A3|1985-03-27|1992-11-27|Method of Acquisition of 1,2-Benzisoxazolyl-3 or 1,2-benzisothiazolyl-3 derivatives or their stereoisomers or their clays-additive islands|

LTRP372A| LT2071B|1985-03-27|1993-02-26|BACKGROUND OF THE INVENTION OF 1,2-BENZYLOSZZZOLO-3 OR 1,2-BENZYLIZOLOLO-3 OR OR STEREOIZE OR SALTS|

[返回顶部]